The FDA has accepted the NDA for zipalertinib to treat adult patients with locally advanced or metastatic EGFR exon 20 insertion-mutated NSCLC.

Datopotamab deruxtecan-dlnk received FDA accelerated approval for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response ...

Please provide your email address to receive an email when new articles are posted on . Patients with an eGFR below the 25th percentile of distribution for their age and sex had greater risks for ...

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...

Hello. It's Mark Kris, from Memorial Sloan Kettering. I'm about to say some things that will not make everyone happy. I would like to comment on a recently published article in The New England Journal ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...

Using a powerful single-molecule imaging method they developed, a Broad Institute research team has unveiled a dynamic view ...

Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside a genetic amplification found in more than half of glioblastoma tumors, ...

Pediatric patients who lived with a low eGFR longer without dialysis had better odds to receive a preemptive or living donor ...